UPDATE: Corrected to reflect that ReWalk Robotics was amending an earlier deal.
ReWalk Robotics (NSDQ:RWLK) has inked a set of amendments to its collaborative research and exclusive licensing agreement with Harvard Collage related to the development of its soft-suit exoskeleton, according to a recently posted SEC filing.
Through the original collaborative deal, both groups will join to aid in the development of soft-suit exoskeleton technologies designed to treat lower limb disabilities, the Marlborough, Mass.-based company said. The suit is intended to treat stroke, multiple sclerosis, mobility limitations for the elderly and other medical applications, ReWalk said.
The new amendments add minor alterations to the licensing agreement, and restructure the language covering how Harvard will receive payments from ReWalk Robotics, according to the SEC filing.
The amendments also change the length of the research agreement, now six years from commencement, and alter language related to the research plan.
The licensing agreement, originally signed in May, grants ReWalk Robotics an exclusive, worldwide royalty-bearing license for certain patents related to the lightweight soft-suit exoskeleton technologies, according to an SEC filing.
The collaborative agreement was inked on May 1, while the licensing deal was signed on April 1, according to the filing.
Last week, ReWalk Robotics said it plans to expand the clinical study of its ReStore soft exo-suit device to five US research centers.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.